Skip to main content
TipRanks
Go Ultimate75% OFF

Zoetis (ZTS) Revenue by Segment

4,109 Followers

Revenue by Segment

Zoetis reported revenue by segment of $2.39B in Q3 2026, down 3.1% from Q2 2026 and down 0.4% year over year. The highest value was $2.47B in Q2 2026.

Breaks down sales by business lines (for example companion‑animal products, livestock products, vaccines, diagnostics), highlighting whether growth and margins come from higher‑value, recurring treatments or from cyclical livestock markets and signaling product concentration or diversification trends.

$0.00$500.00M$1.00B$1.50B$2.00B$2.50BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Companion Animal remains the dominant, seasonally peaking franchise, but those regular Q2 spikes are masking weakening organic momentum — management attributes recent softness to intensified competition, clinic visit declines and gross‑to‑net investments, which prompted guidance cuts. Livestock has emerged as the steady growth offset, delivering durable, higher‑quality expansion from vaccines and demand tailwinds. Manufacturing & Human Health is immaterial to company growth. Cost cuts and buybacks are protecting EPS, but near‑term upside hinges on stabilizing Companion Animal price realization and containing promotional/generic pressures.

ZTS Revenue by Segment

PeriodCompanion AnimalLivestockManufacturing and Human HealthTotal
Q3 2026Sep 30, 2026$1.56B$797.00M$29.00M$2.39B
Q2 2026Jun 30, 2026$1.71B$731.00M$29.00M$2.47B
Q1 2026Mar 31, 2026$1.52B$720.00M$23.00M$2.26B
Q4 2025Dec 31, 2025$1.60B$756.00M$30.00M$2.39B
Q3 2025Sep 30, 2025$1.65B$725.00M$23.00M$2.40B
Q2 2025Jun 30, 2025$1.79B$638.00M$34.00M$2.46B
Q1 2025Mar 31, 2025$1.55B$645.00M$29.00M$2.22B
Q4 2024Dec 31, 2024$1.57B$726.00M$21.00M$2.32B
Q3 2024Sep 30, 2024$1.61B$758.00M$21.00M$2.39B
Q2 2024Jun 30, 2024$1.65B$694.00M$18.00M$2.36B
Q1 2024Mar 31, 2024$1.45B$720.00M$20.00M$2.19B
Q4 2023Dec 31, 2023$1.45B$745.00M$20.00M$2.21B
Q3 2023Sep 30, 2023$1.41B$716.00M$21.00M$2.15B
Q2 2023Jun 30, 2023$1.49B$671.00M$20.00M$2.18B
Q1 2023Mar 31, 2023$1.23B$758.00M$17.00M$2.00B
Q4 2022Dec 31, 2022$1.30B$710.00M$27.00M$2.04B
Q3 2022Sep 30, 2022$1.27B$708.00M$23.00M$2.00B
Q2 2022Jun 30, 2022$1.37B$668.00M$18.00M$2.05B
Q1 2022Mar 31, 2022$1.26B$705.00M$18.00M$1.99B
Q4 2021Dec 31, 2021$1.18B$760.00M$25.00M$1.97B
Q3 2021Sep 30, 2021$1.20B$767.00M$21.00M$1.99B
Q2 2021Jun 30, 2021$1.23B$699.00M$20.00M$1.95B
Q1 2021Mar 31, 2021$1.08B$779.00M$16.00M$1.87B
Q4 2020Dec 31, 2020$978.00M$806.00M$23.00M$1.81B
Q3 2020Sep 30, 2020$995.00M$768.00M$23.00M$1.79B
Q2 2020Jun 30, 2020$882.00M$649.00M$17.00M$1.55B
Q1 2020Mar 31, 2020$797.00M$717.00M$20.00M$1.53B
Q4 2019Dec 31, 2019$784.00M$868.00M$22.00M$1.67B
Q3 2019Sep 30, 2019$834.00M$731.00M$19.00M$1.58B
Q2 2019Jun 30, 2019$798.00M$724.00M$25.00M$1.55B
Q1 2019Mar 31, 2019$729.00M$707.00M$19.00M$1.46B
Q4 2018Dec 31, 2018$664.00M$872.00M$28.00M$1.56B
Q3 2018Sep 30, 2018$688.00M$778.00M$14.00M$1.48B
Q2 2018Jun 30, 2018$671.00M$734.00M$16.00M$1.42B
Q1 2018Mar 31, 2018$590.00M$770.00M$6.00M$1.37B
Q4 2017Dec 31, 2017$561.00M$891.00M$8.00M$1.46B
Q3 2017Sep 30, 2017$580.00M$754.00M$13.00M$1.35B
Q2 2017Jun 30, 2017$568.00M$689.00M$23.00M$1.28B
Q1 2017Mar 31, 2017$517.00M$703.00M$11.00M$1.23B
Q4 2016Dec 31, 2016$477.00M$790.00M$10.00M$1.28B
Q3 2016Sep 30, 2016$490.00M$735.00M$16.00M$1.24B
Q2 2016Jun 30, 2016$523.00M$673.00M$12.00M$1.21B
Q1 2016Mar 31, 2016$466.00M$683.00M$13.00M$1.16B
Q4 2015Dec 31, 2015$457.00M$803.00M$14.00M$1.27B
Q3 2015Sep 30, 2015$451.00M$750.00M$13.00M$1.21B
Q2 2015Jun 30, 2015$471.00M$690.00M$14.00M$1.18B
Q1 2015Mar 31, 2015$377.00M$715.00M$10.00M$1.10B
Q4 2014Dec 31, 2014$405.00M$904.00M$11.00M$1.32B
Q3 2014Sep 30, 2014$408.00M$790.00M$12.00M$1.21B
Q2 2014Jun 30, 2014$439.00M$703.00M$16.00M$1.16B
Q1 2014Mar 31, 2014$380.00M$706.00M$11.00M$1.10B
Q4 2013Dec 31, 2013$405.00M$849.00M$16.00M$1.27B
Q3 2013Sep 30, 2013$387.00M$702.00M$14.00M$1.10B
Q2 2013Jun 30, 2013$435.00M$667.00M$12.00M$1.11B
Q1 2013Jan 31, 2013$376.00M$703.00M$11.00M$1.09B
Q4 2012Dec 31, 2012$385.00M$791.00M$0.00$1.18B

Related KPIs